既往TAVR与SAVR后再次主动脉瓣置换:合并瓣膜病增加手术风险
基于STS成人心脏手术数据库2011-2021年24,097例再次主动脉瓣置换患者,877例(3.6%)为TAVR瓣膜取出。TAVR取出患者合并严重瓣膜病比例更高(17% vs 14%),且合并严重瓣膜病者TAVR取出后手术死亡率达26.2%。TAVR取出独立与较高死亡率相关(ORadj 1.3),二尖瓣狭窄、三尖瓣反流等亦与死亡率相关。
要点
- TAVR取出患者合并严重瓣膜病比例高于再次SAVR(17% vs 14%)。
- 合并严重瓣膜病者TAVR取出后手术死亡率26.2%,再次SAVR为12.3%。
- 心脏团队在多瓣膜病患者初始选择术式时应考虑TAVR取出时的高风险。
核心结论
- TAVR取出病例的严重合并瓣膜病负担高于再次SAVR病例,且合并严重瓣膜病者在TAVR取出时手术死亡风险极高。
研究设计与样本
- 回顾性队列研究,数据来自STS成人心脏手术数据库(2011-2021),纳入24,097例既往SAVR或TAVR后再次主动脉瓣置换患者,其中877例(3.6%)为TAVR取出。
- 采用多变量logistic回归进行风险调整,并使用交互项评估合并瓣膜病对TAVR取出与再次SAVR风险的差异。
主要发现
- TAVR取出患者合并严重瓣膜病比例为17%,再次SAVR为14%(P < .001)。
- 合并严重瓣膜病者TAVR取出后手术死亡率为26.2%,无严重合并瓣膜病者为14.6%(P < .001)。
- 合并严重瓣膜病者再次SAVR后手术死亡率为12.3%,无严重合并瓣膜病者为6.9%(P < .001)。
- TAVR取出独立与较高死亡率相关(ORadj 1.3 [1.0-1.6];P = .030)。
- 严重二尖瓣反流(ORadj 1.2 [1.0-1.6];P = .017)、二尖瓣狭窄(ORadj 2.0 [1.5-2.7];P < .001)和三尖瓣反流(ORadj 1.6 [1.3-1.9];P < .001)均与死亡率相关,但这些因素并未与TAVR取出产生显著交互作用(P > .05)。
临床怎么用
- 心脏团队在为多瓣膜病患者讨论初始术式选择时,应考虑TAVR取出时合并严重瓣膜病带来的极高手术风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cause of increased risk for reoperation after transcatheter aortic valve replacement (TAVR) vs prior surgical aortic valve replacement (SAVR) is poorly understood. This study evaluated the impact of concomitant mitral and tricuspid valve disease on associated risk of TAVR explantation. METHODS: Patients undergoing aortic valve replacement after prior SAVR or TAVR were extracted from The Society of Thoracic Surgeons Adult Cardiac Surgery Database (2011-2021). Patients were stratified by TAVR explantation status and presence of severe concomitant valve disease for analyses. Risk adjustment was performed by multivariable logistic regression. Interaction terms were used to evaluate differential risk of concomitant valve disease for TAVR explantation vs redo-SAVR. RESULTS: Of 24,097 redo aortic valve replacement patients, 877 (3.6%) underwent TAVR explantation. TAVR explantation patients had higher rates of concomitant severe valve disease (17% vs 14%; P < .001). Patients with severe concomitant valve disease had worse operative mortality after TAVR explantation (26.2% vs 14.6%; P < .001) and redo-SAVR (12.3% vs 6.9%; p < .001). TAVR explantation was independently associated with higher mortality (adjusted odds ratio [ORadj], 1.3 [1.0-1.6]; P = .030). Severe mitral regurgitation (ORadj, 1.2 [1.0-1.6]; P = .017), mitral stenosis (ORadj, 2.0 [1.5-2.7; P < .001), and tricuspid regurgitation (ORadj, 1.6 [1.3-1.9]; P < .001) were all associated with mortality, although these factors were not associated with disproportionately higher risk during TAVR explantation (P > .05). CONCLUSIONS: TAVR explantation cases have a higher burden of severe concomitant valve disease than redo-SAVR cases. Heart teams should consider these findings when discussing initial procedure choices for patients with multivalve disease, given their extreme risk at time of TAVR explantation.
引用
- Hawkins RB, Hamilton BCS, Sukul D, et al. Increased Risk of Surgical Aortic Valve Replacement After Prior Transcatheter vs Surgical Aortic Valve Replacement With Concomitant Valve Disease. Ann Thorac Surg. 2025. PMID: 39864774. doi:10.1016/j.athoracsur.2025.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。